Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

• DOI: 10.1200/jco.22.02516
• Publication Date: 2023-03-15T22:01:08Z
• Authors: Charles L. Vogel; Melody A. Cobleigh; Debu Tripathy; John C. Gutheil; Lyndsay N. Harris; Louis Fehrenbacher; Dennis J. Slamon; Maureen Murphy; William F. Novotny; Michael Burchmore; Steven Shak; Stanford J. Stewart; Michael Press
• Keywords: Chills; Discontinuation

To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with